Laboratory of Immunoinflammation, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP) , Campinas, Brazil.
Inflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP) , Campinas, Brazil.
Gut Microbes. 2021 Jan-Dec;13(1):1-9. doi: 10.1080/19490976.2021.1874740.
Microbiota-derived molecules called short-chain fatty acids (SCFAs) play a key role in the maintenance of the intestinal barrier and regulation of immune response during infectious conditions. Recent reports indicate that SARS-CoV-2 infection changes microbiota and SCFAs production. However, the relevance of this effect is unknown. In this study, we used human intestinal biopsies and intestinal epithelial cells to investigate the impact of SCFAs in the infection by SARS-CoV-2. SCFAs did not change the entry or replication of SARS-CoV-2 in intestinal cells. These metabolites had no effect on intestinal cells' permeability and presented only minor effects on the production of anti-viral and inflammatory mediators. Together our findings indicate that the changes in microbiota composition of patients with COVID-19 and, particularly, of SCFAs do not interfere with the SARS-CoV-2 infection in the intestine.
微生物衍生的分子，称为短链脂肪酸 (SCFAs)，在维持肠道屏障和调节感染条件下的免疫反应方面发挥着关键作用。最近的报告表明，SARS-CoV-2 感染会改变微生物群和 SCFA 的产生。然而，这种影响的相关性尚不清楚。在这项研究中，我们使用人类肠道活检和肠上皮细胞来研究 SCFA 对 SARS-CoV-2 感染的影响。SCFA 不会改变 SARS-CoV-2 在肠道细胞中的进入或复制。这些代谢物对肠道细胞的通透性没有影响，对抗病毒和炎症介质的产生只有很小的影响。我们的研究结果表明，COVID-19 患者的微生物组组成变化，特别是 SCFA 的变化，不会干扰 SARS-CoV-2 在肠道中的感染。
